20241-57-0Relevant articles and documents
Method for preparing high-purity 4,4'-oxybisbenzensulfonyl chloride
-
Paragraph 0018-0023, (2017/08/28)
The invention discloses a method for preparing high-purity 4,4'-oxybisbenzensulfonyl chloride. The method includes the following steps that (1) concentrated sulfuric acid is dropwise added into diphenyl ether at the temperature of 60 DEG C and the negative pressure, the mixture is fully reacted at the temperature of 130 DEG C to 140 DEG C after the concentrated sulfuric acid is dropwise added, the reaction is completed, and a sulfonic acid mixture is prepared; (2) an organic solvent is added into the sulfonic acid mixture at the temperature of 0 DEG C to 30 DEG C, the pH value of a system is adjusted to be 7 to 9 with alkali, solid-liquid separation is carried out, and diphenyl ether disulfonate is obtained; (3) the diphenyl ether disulfonate is added into acid, the mixture is fully reacted, water is removed after reacting, and a mixed product is obtained; (4) phosphorus oxychloride is dropwise added into the mixed product at the temperature of 80 DEG C or above, the mixture is fully reacted after the temperature of 100 DEG C to 105 DEG C after the phosphorus oxychloride is dropwise added, a reaction product is obtained after reacting, the reaction product is washed, and the 4,4'-oxybisbenzensulfonyl chloride is obtained. OBSC prepared with the method is narrow in melting range, high in purity and whiteness degree and capable of allowing a downstream product foaming agent OBSH to have the advantages of being high in gas-forming amount, narrow in gas-forming temperature range and high in purity and whiteness degree.
Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors
Amelia Santos,Marques, Sergio M.,Tuccinardi, Tiziano,Carelli, Paolo,Panelli, Laura,Rossello, Armando
, p. 7539 - 7550 (2008/02/09)
As the matrix metalloproteinases (MMPs) can be massively up-regulated in degenerative tissues and degrade the extracellular matrix, these key enzymes are promising targets for the therapy of cancer and other degenerative diseases. Here, we are presenting a series of new non-peptidic hydroxamate-based matrix metalloproteinase inhibitors, MMPIs, incorporating the iminodiacetic (IDA) hydroxamic acid scaffold, as mimics of truncated peptidic MMPIs. A series of alkylaryl and sulfonylaryl groups, on the IDA basic scaffold, was investigated with the aim of improving potency and selectivity against MMPs involved in degenerative diseases. The sulfonamide based IDA derivatives studied (compounds B1-B3) showed to be potent (nM range) against deep S1′ pocket MMPs enzymes (i.e., MMP-2).
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
-
, (2008/06/13)
The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.
